$ADPT Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Adaptive Biotechnologies Corp.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Adaptive Biotechnologies Corp. Get notifications about new insider transactions in Adaptive Biotechnologies Corp for free.
Page: < prev 1 ... 3 4 5 6 7 8 9 10 11 ... 11 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 09 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Option Exercise | M | 6.32 | 20,000 | 126,400 | 590,000 | |
| Sep 09 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 36.17 | 20,000 | 723,400 | 1,000 | 21 K to 1,000 (-95.24 %) |
| Sep 09 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Buy | M | 6.32 | 20,000 | 126,400 | 21,000 | 1,000 to 21 K (+2,000.00 %) |
| Sep 09 2020 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Option Exercise | M | 7.80 | 2,083 | 16,247 | 429,167 | |
| Sep 09 2020 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Sell | S | 36.17 | 2,083 | 75,342 | 0 | 2.1 K to 0 (-100.00 %) |
| Sep 09 2020 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Buy | M | 7.80 | 2,083 | 16,247 | 2,083 | 0 to 2.1 K |
| Sep 02 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Option Exercise | M | 7.27 | 1,563 | 11,363 | 43,750 | |
| Sep 02 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Option Exercise | M | 6.55 | 2,604 | 17,056 | 65,105 | |
| Sep 02 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Option Exercise | M | 6.55 | 2,604 | 17,056 | 36,459 | |
| Sep 02 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Sell | S | 41.75 | 300 | 12,525 | 0 | 300 to 0 (-100.00 %) |
| Sep 02 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Sell | S | 41.28 | 6,471 | 267,123 | 300 | 6.8 K to 300 (-95.57 %) |
| Sep 02 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Buy | M | 7.27 | 1,563 | 11,363 | 6,771 | 5.2 K to 6.8 K (+30.01 %) |
| Sep 02 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Buy | M | 6.55 | 2,604 | 17,056 | 5,208 | 2.6 K to 5.2 K (+100.00 %) |
| Sep 02 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Buy | M | 6.55 | 2,604 | 17,056 | 2,604 | 0 to 2.6 K |
| Aug 24 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 11,100 | 70,152 | 333,600 | |
| Aug 24 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 11,100 | 70,152 | 344,700 | |
| Aug 24 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 11,100 | 70,152 | 355,800 | |
| Aug 24 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 43.14 | 10,750 | 463,755 | 679 | 11.4 K to 679 (-94.06 %) |
| Aug 24 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 42.58 | 350 | 14,903 | 11,429 | 11.8 K to 11.4 K (-2.97 %) |
| Aug 24 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 11,100 | 70,152 | 11,779 | 679 to 11.8 K (+1,634.76 %) |
| Aug 24 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 43.35 | 4,630 | 200,711 | 679 | 5.3 K to 679 (-87.21 %) |
| Aug 24 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 42.63 | 6,470 | 275,816 | 5,309 | 11.8 K to 5.3 K (-54.93 %) |
| Aug 24 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 11,100 | 70,152 | 11,779 | 679 to 11.8 K (+1,634.76 %) |
| Aug 24 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 42.91 | 6,900 | 296,079 | 679 | 7.6 K to 679 (-91.04 %) |
| Aug 24 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 41.77 | 4,200 | 175,434 | 7,579 | 11.8 K to 7.6 K (-35.66 %) |
| Aug 24 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 11,100 | 70,152 | 11,779 | 679 to 11.8 K (+1,634.76 %) |
| Aug 24 2020 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Option Exercise | M | 6.55 | 1,771 | 11,600 | 33,646 | |
| Aug 24 2020 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Option Exercise | M | 7.80 | 1,109 | 8,650 | 37,254 | |
| Aug 24 2020 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Sell | S | 43.36 | 220 | 9,539 | 1,300 | 1.5 K to 1.3 K (-14.47 %) |
| Aug 24 2020 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Sell | S | 42.92 | 1,400 | 60,088 | 1,520 | 2.9 K to 1.5 K (-47.95 %) |
| Aug 24 2020 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Sell | S | 42.07 | 1,260 | 53,008 | 2,920 | 4.2 K to 2.9 K (-30.14 %) |
| Aug 24 2020 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Buy | M | 6.55 | 1,771 | 11,600 | 4,180 | 2.4 K to 4.2 K (+73.52 %) |
| Aug 24 2020 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Buy | M | 7.80 | 1,109 | 8,650 | 2,409 | 1.3 K to 2.4 K (+85.31 %) |
| Aug 19 2020 | ADPT | Adaptive Biotechno ... | LO FRANCIS | Chief People Office ... | Option Exercise | M | 7.80 | 2,000 | 15,600 | 194,000 | |
| Aug 19 2020 | ADPT | Adaptive Biotechno ... | LO FRANCIS | Chief People Office ... | Sell | S | 40.01 | 561 | 22,446 | 0 | 561 to 0 (-100.00 %) |
| Aug 19 2020 | ADPT | Adaptive Biotechno ... | LO FRANCIS | Chief People Office ... | Sell | S | 39.11 | 1,439 | 56,279 | 561 | 2 K to 561 (-71.95 %) |
| Aug 19 2020 | ADPT | Adaptive Biotechno ... | LO FRANCIS | Chief People Office ... | Buy | M | 7.80 | 2,000 | 15,600 | 2,000 | 0 to 2 K |
| Aug 19 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Option Exercise | M | 6.27 | 416 | 2,608 | 3,334 | |
| Aug 19 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Sell | S | 41.57 | 416 | 17,293 | 0 | 416 to 0 (-100.00 %) |
| Aug 19 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Buy | M | 6.27 | 416 | 2,608 | 416 | 0 to 416 |
| Aug 19 2020 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Option Exercise | M | 0.45 | 2,000 | 900 | 67,000 | |
| Aug 19 2020 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Sell | S | 40.04 | 561 | 22,462 | 0 | 561 to 0 (-100.00 %) |
| Aug 19 2020 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Sell | S | 39.13 | 1,439 | 56,308 | 561 | 2 K to 561 (-71.95 %) |
| Aug 19 2020 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Buy | M | 0.45 | 2,000 | 900 | 2,000 | 0 to 2 K |
| Aug 19 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Option Exercise | M | 6.32 | 10,000 | 63,200 | 610,000 | |
| Aug 19 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 40.00 | 10,000 | 400,000 | 1,000 | 11 K to 1,000 (-90.91 %) |
| Aug 19 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Buy | M | 6.32 | 10,000 | 63,200 | 11,000 | 1,000 to 11 K (+1,000.00 %) |
| Aug 14 2020 | ADPT | Adaptive Biotechno ... | BOBULSKY SUSAN | SVP, Diagnostics, c ... | Option Exercise | A | 39.50 | 20,000 | 790,000 | 20,000 | |
| Aug 14 2020 | ADPT | Adaptive Biotechno ... | BOBULSKY SUSAN | SVP, Diagnostics, c ... | Option Exercise | A | 39.50 | 20,000 | 790,000 | 20,000 | |
| Aug 12 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Option Exercise | M | 0.33 | 16,680 | 5,504 | 244,680 | |
| Aug 12 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Option Exercise | M | 0.33 | 16,680 | 5,504 | 261,360 | |
| Aug 12 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Option Exercise | M | 0.33 | 16,680 | 5,504 | 278,040 | |
| Aug 12 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Buy | S | 38.43 | 9,005 | 346,062 | 1,778,180 | 1.8 M to 1.8 M (+0.51 %) |
| Aug 12 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 37.50 | 6,774 | 254,025 | 1,787,185 | 1.8 M to 1.8 M (-0.38 %) |
| Aug 12 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 36.80 | 901 | 33,157 | 1,793,959 | 1.8 M to 1.8 M (-0.05 %) |
| Aug 12 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Buy | M | 0.33 | 16,680 | 5,504 | 1,794,860 | 1.8 M to 1.8 M (+0.94 %) |
| Aug 12 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 37.96 | 2,000 | 75,920 | 1,778,180 | 1.8 M to 1.8 M (-0.11 %) |
| Aug 12 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 37.40 | 9,743 | 364,388 | 1,780,180 | 1.8 M to 1.8 M (-0.54 %) |
| Aug 12 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 36.51 | 4,937 | 180,250 | 1,789,923 | 1.8 M to 1.8 M (-0.28 %) |
| Aug 12 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Buy | M | 0.33 | 16,680 | 5,504 | 1,794,860 | 1.8 M to 1.8 M (+0.94 %) |
| Aug 12 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 37.63 | 16,680 | 627,668 | 1,778,180 | 1.8 M to 1.8 M (-0.93 %) |
| Aug 12 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Buy | M | 0.33 | 16,680 | 5,504 | 1,794,860 | 1.8 M to 1.8 M (+0.94 %) |
| Aug 12 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Option Exercise | M | 6.32 | 20,000 | 126,400 | 620,000 | |
| Aug 12 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 37.78 | 20,000 | 755,600 | 1,000 | 21 K to 1,000 (-95.24 %) |
| Aug 12 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Buy | M | 6.32 | 20,000 | 126,400 | 21,000 | 1,000 to 21 K (+2,000.00 %) |
| Aug 07 2020 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Option Exercise | M | 7.80 | 6,250 | 48,750 | 431,250 | |
| Aug 07 2020 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Sell | S | 40.00 | 6,250 | 250,000 | 0 | 6.3 K to 0 (-100.00 %) |
| Aug 07 2020 | ADPT | Adaptive Biotechno ... | BALDO LANCE | Chief Medical Offic ... | Buy | M | 7.80 | 6,250 | 48,750 | 6,250 | 0 to 6.3 K |
| Aug 05 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Option Exercise | M | 6.32 | 417 | 2,635 | 0 | |
| Aug 05 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Option Exercise | M | 7.27 | 1,562 | 11,356 | 45,313 | |
| Aug 05 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Option Exercise | M | 6.55 | 2,604 | 17,056 | 67,709 | |
| Aug 05 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Option Exercise | M | 6.55 | 2,604 | 17,056 | 39,063 | |
| Aug 05 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Sell | S | 40.00 | 7,187 | 287,480 | 0 | 7.2 K to 0 (-100.00 %) |
| Aug 05 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Buy | M | 6.32 | 417 | 2,635 | 7,187 | 6.8 K to 7.2 K (+6.16 %) |
| Aug 05 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Buy | M | 7.27 | 1,562 | 11,356 | 6,770 | 5.2 K to 6.8 K (+29.99 %) |
| Aug 05 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Buy | M | 6.55 | 2,604 | 17,056 | 5,208 | 2.6 K to 5.2 K (+100.00 %) |
| Aug 05 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Buy | M | 6.55 | 2,604 | 17,056 | 2,604 | 0 to 2.6 K |
| Aug 05 2020 | ADPT | Adaptive Biotechno ... | HILL NANCY LOUISE | EVP, Operations & P ... | Option Exercise | M | 0.84 | 1,600 | 1,344 | 99,000 | |
| Aug 05 2020 | ADPT | Adaptive Biotechno ... | HILL NANCY LOUISE | EVP, Operations & P ... | Sell | S | 37.37 | 1,600 | 59,792 | 10,000 | 11.6 K to 10 K (-13.79 %) |
| Aug 05 2020 | ADPT | Adaptive Biotechno ... | HILL NANCY LOUISE | EVP, Operations & P ... | Buy | M | 0.84 | 1,600 | 1,344 | 11,600 | 10 K to 11.6 K (+16.00 %) |
| Jul 31 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Option Exercise | M | 0.33 | 16,680 | 5,504 | 294,720 | |
| Jul 31 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Option Exercise | M | 0.33 | 16,680 | 5,504 | 294,720 | |
| Jul 31 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Option Exercise | M | 0.33 | 16,680 | 5,504 | 311,400 | |
| Jul 31 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Option Exercise | M | 0.33 | 16,680 | 5,504 | 311,400 | |
| Jul 31 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Option Exercise | M | 0.33 | 20,668 | 6,820 | 328,080 | |
| Jul 31 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Option Exercise | M | 0.33 | 20,668 | 6,820 | 328,080 | |
| Jul 31 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 37.79 | 1,200 | 45,348 | 1,778,180 | 1.8 M to 1.8 M (-0.07 %) |
| Jul 31 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 37.79 | 1,200 | 45,348 | 1,778,180 | 1.8 M to 1.8 M (-0.07 %) |
| Jul 31 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 37.19 | 15,480 | 575,701 | 1,779,380 | 1.8 M to 1.8 M (-0.86 %) |
| Jul 31 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 37.19 | 15,480 | 575,701 | 1,779,380 | 1.8 M to 1.8 M (-0.86 %) |
| Jul 31 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Buy | M | 0.33 | 16,680 | 5,504 | 1,794,860 | 1.8 M to 1.8 M (+0.94 %) |
| Jul 31 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Buy | M | 0.33 | 16,680 | 5,504 | 1,794,860 | 1.8 M to 1.8 M (+0.94 %) |
| Jul 31 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 37.96 | 9,884 | 375,197 | 1,778,180 | 1.8 M to 1.8 M (-0.55 %) |
| Jul 31 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 37.96 | 9,884 | 375,197 | 1,778,180 | 1.8 M to 1.8 M (-0.55 %) |
| Jul 31 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 37.48 | 6,796 | 254,714 | 1,788,064 | 1.8 M to 1.8 M (-0.38 %) |
| Jul 31 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 37.48 | 6,796 | 254,714 | 1,788,064 | 1.8 M to 1.8 M (-0.38 %) |
| Jul 31 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Buy | M | 0.33 | 16,680 | 5,504 | 1,794,860 | 1.8 M to 1.8 M (+0.94 %) |
| Jul 31 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Buy | M | 0.33 | 16,680 | 5,504 | 1,794,860 | 1.8 M to 1.8 M (+0.94 %) |
| Jul 31 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 38.14 | 20,668 | 788,278 | 1,778,180 | 1.8 M to 1.8 M (-1.15 %) |
| Jul 31 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 38.14 | 20,668 | 788,278 | 1,778,180 | 1.8 M to 1.8 M (-1.15 %) |
| Jul 31 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Buy | M | 0.33 | 20,668 | 6,820 | 1,798,848 | 1.8 M to 1.8 M (+1.16 %) |
| Jul 31 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Buy | M | 0.33 | 20,668 | 6,820 | 1,798,848 | 1.8 M to 1.8 M (+1.16 %) |
| Jul 24 2020 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Option Exercise | M | 6.55 | 1,771 | 11,600 | 35,417 | |
| Jul 24 2020 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Option Exercise | M | 7.80 | 1,109 | 8,650 | 38,363 | |
| Jul 24 2020 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Sell | S | 36.03 | 2,880 | 103,766 | 1,300 | 4.2 K to 1.3 K (-68.90 %) |
| Jul 24 2020 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Buy | M | 6.55 | 1,771 | 11,600 | 4,180 | 2.4 K to 4.2 K (+73.52 %) |
| Jul 24 2020 | ADPT | Adaptive Biotechno ... | Taylor Stacy L | SVP and General Cou ... | Buy | M | 7.80 | 1,109 | 8,650 | 2,409 | 1.3 K to 2.4 K (+85.31 %) |
| Jul 22 2020 | ADPT | Adaptive Biotechno ... | GOEL DAVID E. | Director | Sell | S | 40.00 | 2,000,000 | 80,000,000 | 13,115,090 | 15.1 M to 13.1 M (-13.23 %) |
| Jul 21 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Option Exercise | M | 6.27 | 417 | 2,615 | 3,750 | |
| Jul 21 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Sell | S | 40.00 | 417 | 16,680 | 0 | 417 to 0 (-100.00 %) |
| Jul 21 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Buy | M | 6.27 | 417 | 2,615 | 417 | 0 to 417 |
| Jul 17 2020 | ADPT | Adaptive Biotechno ... | LO FRANCIS | Chief People Office ... | Option Exercise | M | 7.80 | 2,000 | 15,600 | 196,000 | |
| Jul 17 2020 | ADPT | Adaptive Biotechno ... | LO FRANCIS | Chief People Office ... | Option Exercise | M | 7.80 | 2,000 | 15,600 | 196,000 | |
| Jul 17 2020 | ADPT | Adaptive Biotechno ... | LO FRANCIS | Chief People Office ... | Sell | S | 44.56 | 500 | 22,280 | 0 | 500 to 0 (-100.00 %) |
| Jul 17 2020 | ADPT | Adaptive Biotechno ... | LO FRANCIS | Chief People Office ... | Sell | S | 44.56 | 500 | 22,280 | 0 | 500 to 0 (-100.00 %) |
| Jul 17 2020 | ADPT | Adaptive Biotechno ... | LO FRANCIS | Chief People Office ... | Sell | S | 43.62 | 1,500 | 65,430 | 500 | 2 K to 500 (-75.00 %) |
| Jul 17 2020 | ADPT | Adaptive Biotechno ... | LO FRANCIS | Chief People Office ... | Sell | S | 43.62 | 1,500 | 65,430 | 500 | 2 K to 500 (-75.00 %) |
| Jul 17 2020 | ADPT | Adaptive Biotechno ... | LO FRANCIS | Chief People Office ... | Buy | M | 7.80 | 2,000 | 15,600 | 2,000 | 0 to 2 K |
| Jul 17 2020 | ADPT | Adaptive Biotechno ... | LO FRANCIS | Chief People Office ... | Buy | M | 7.80 | 2,000 | 15,600 | 2,000 | 0 to 2 K |
| Jul 17 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 11,100 | 70,152 | 366,900 | |
| Jul 17 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 11,100 | 70,152 | 366,900 | |
| Jul 17 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 22,200 | 140,304 | 378,000 | |
| Jul 17 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 22,200 | 140,304 | 378,000 | |
| Jul 17 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 40.23 | 1,706 | 68,632 | 679 | 2.4 K to 679 (-71.53 %) |
| Jul 17 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 40.23 | 1,706 | 68,632 | 679 | 2.4 K to 679 (-71.53 %) |
| Jul 17 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 39.62 | 8,194 | 324,646 | 2,385 | 10.6 K to 2.4 K (-77.46 %) |
| Jul 17 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 39.62 | 8,194 | 324,646 | 2,385 | 10.6 K to 2.4 K (-77.46 %) |
| Jul 17 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 38.61 | 1,200 | 46,332 | 10,579 | 11.8 K to 10.6 K (-10.19 %) |
| Jul 17 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 38.61 | 1,200 | 46,332 | 10,579 | 11.8 K to 10.6 K (-10.19 %) |
| Jul 17 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 11,100 | 70,152 | 11,779 | 679 to 11.8 K (+1,634.76 %) |
| Jul 17 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 11,100 | 70,152 | 11,779 | 679 to 11.8 K (+1,634.76 %) |
| Jul 17 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 39.92 | 7,380 | 294,610 | 679 | 8.1 K to 679 (-91.57 %) |
| Jul 17 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 39.92 | 7,380 | 294,610 | 679 | 8.1 K to 679 (-91.57 %) |
| Jul 17 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 39.39 | 14,820 | 583,760 | 8,059 | 22.9 K to 8.1 K (-64.78 %) |
| Jul 17 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 39.39 | 14,820 | 583,760 | 8,059 | 22.9 K to 8.1 K (-64.78 %) |
| Jul 17 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 22,200 | 140,304 | 22,879 | 679 to 22.9 K (+3,269.51 %) |
| Jul 17 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 22,200 | 140,304 | 22,879 | 679 to 22.9 K (+3,269.51 %) |
| Jul 17 2020 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Option Exercise | M | 0.45 | 2,000 | 900 | 69,000 | |
| Jul 17 2020 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Sell | S | 44.58 | 500 | 22,290 | 0 | 500 to 0 (-100.00 %) |
| Jul 17 2020 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Option Exercise | M | 0.45 | 2,000 | 900 | 69,000 | |
| Jul 17 2020 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Sell | S | 43.60 | 1,500 | 65,400 | 500 | 2 K to 500 (-75.00 %) |
| Jul 17 2020 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Sell | S | 44.58 | 500 | 22,290 | 0 | 500 to 0 (-100.00 %) |
| Jul 17 2020 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Buy | M | 0.45 | 2,000 | 900 | 2,000 | 0 to 2 K |
| Jul 17 2020 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Sell | S | 43.60 | 1,500 | 65,400 | 500 | 2 K to 500 (-75.00 %) |
| Jul 17 2020 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Buy | M | 0.45 | 2,000 | 900 | 2,000 | 0 to 2 K |
| Jul 10 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Option Exercise | M | 6.32 | 30,000 | 189,600 | 640,000 | |
| Jul 10 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 47.52 | 2,104 | 99,982 | 1,000 | 3.1 K to 1,000 (-67.78 %) |
| Jul 10 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 46.82 | 27,896 | 1,306,091 | 3,104 | 31 K to 3.1 K (-89.99 %) |
| Jul 10 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Buy | M | 6.32 | 30,000 | 189,600 | 31,000 | 1,000 to 31 K (+3,000.00 %) |
| Jul 10 2020 | ADPT | Adaptive Biotechno ... | RUBINSTEIN JULIE | President | Option Exercise | M | 0.84 | 15,275 | 12,831 | 94,725 |